Science first
Every engagement starts with a critical read of the underlying biology, the data, and the IP. Capital and strategy follow conviction in the science, not the other way around.
Approach
A disciplined, operator-led model for biotech venture building.
We bring capital and senior advisory to a selected small number of biotech ventures where we can be materially helpful.
Path to patients
We back programs with a credible translational path: defined indication, regulatory route, and a clinical plan that respects the cost of capital.
Operator perspective
Over three decades of building, financing and partnering biotech companies shape how we structure rounds, model value, and negotiate deals.
Long-term involvement
We stay engaged through the milestones that matter, from seed round through partnership, out-licensing, or acquisition.
Engagement model
From first conversation to realization.
- 01DiligenceScientific, IP, competitive and financial assessment of the opportunity.
- 02StructureInvestor materials, financing structure and syndicate construction.
- 03CapitalizeDirect investment and introductions to aligned angel and venture investors.
- 04BuildStrategic planning, BD execution and partnership sourcing alongside the team.
- 05RealizeOut-licensing, joint development or M&A execution at the right inflection point.